RE:RE:RE:RE:RE:NewsI'd be happy with some nice financials for a while. Investors are currently sick of the acquire through growth accounting shell game that Valeant made popular. NHC, PHM, Concordia, Valeant - it's al the rollup companies that are getting hardest hit simply because they have too much business development and not enough organic earnings growth. A 20% rise in organic earnings would probably help a drug company much more in this market than another acquisition or licensing deal. Short sighted I know, but I am growing tired of these roll up companies slaughtering the whole sector because they think they can put one over on investors with an elaborate shell game. I hope Nobilis and PHM go to zero. Someone will have to explain to me - outside of using the word 'synergy' - why a bunch of garbage piled into a huge pile of garbage is worth more than the sum of its parts. *shrug*